Mutations in STK11 and KEAP1 are associated with resistance to ICI treatment in lung adenocarcinoma [9], but these mutations are difficult to sufficiently predict the efficacy of ICI treatment in SMARCA4-UT [5]. This evidence concerns the gene SMARCA4 and lung adenocarcinoma.